News

Early data on Selagine, Inc.’s immunoglobulin eye drops have indicated significant reductions in DED symptoms without differences in adverse events or tolerability.

AC-201 at 25, 50, and 100 mg doses show promising phase 2 results, significantly reducing psoriasis severity.

The approval adds to Ritestar’s currently approved albuterol sulfate 2.5 mg/3 mL (0.083%), 1.25 mg/3 mL, and 0.63 mg/3 mL strength products.

High cow’s milk- and casein-specific IgE levels were key risk factors for reactions, including anaphylaxis, during low-dose oral food challenges in children.

Abramson discusses the potential benefits and limitations of treatment methods for Coats’ disease and further discusses the genetic component of its pathology.

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

In this episode, hosts explore real-world data on Beta Bionics' iLet automated insulin delivery system for diabetes management.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.

Veligrotug shows promising long-term Phase 3 results for treating thyroid eye disease, supporting its BLA submission in the second half of 2025.

In this interview at ATS 2025, Arthur Reingold, MD, highlights the role of pulmonologists and other health care providers in combatting vaccine misinformation.

The allergy medications of cetirizine or levocetirizine have led to pruritus in some patients who stopped using the medications after using them daily for a few months or years.

Marchetti explains the benefits of assessing RV/TLC rather than absolute RV to determine the efficacy of BLVR in patients with emphysema and hyperinflation.

Shultz discusses the impact of lotilaner ophthalmic solution 0.25% to treat active Demodex blepharitis in patients with meibomian gland dysfunction.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

Miranti shared 2025 acne and rosacea trends, as well as an overlapping treatment option for patients with both conditions, at New Wave Dermatology.

Abramson's presented operation indicates that Coats disease can manifest bilaterally and is potentially caused by multiple independent genes.

Williams discusses her takeaways from the 2025 Envision conference and her expectations for the future of both ophthalmology and its practitioners.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

A post-hoc analysis of SURMOUNT-OSA highlights tirzepatide’s consistent benefit across all baseline OSA severity groups.

The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

The pooled analysis of ENHANCE clinical trial program data highlight improvements in HRQoL, dyspnea, and COPD symptoms with ensifentrine monotherapy.

Nearly all treated patients received glucocorticoids, but many quickly needed later-line therapies, especially those with non-incident pulmonary sarcoidosis.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.